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Introducing Magnesium Sulphate for the
Management of Pregnancy Induced
Hypertension
Global studies1 have demonstrated that usingmagnesium sulphate (MgSO4) to manage
hypertensive disease in pregnancy, reduces
morbidity and mortality due to severe pre
eclampsia and eclampsia, one of the five direct
causes of maternal death.  Major signs of pre
eclampsia/eclampsia include high blood
pressure, protein in the urine, swelling of the
feet, hands and face leading to convulsions
(fitting) and coma.
Women are not always given anti hypertensives
to control the high blood pressure and
Diazepam is often the only drug used to control
eclamptic fits. However this is a sedative and
not an anticonvulsant. MgSO4 on the other
hand does not sedate pregnant women and
they are alert throughout.
Many countries have been slow to introduce
MgSO4 to the detriment of women’s health.
Hypertensive disease in pregnancy  (Eclampsia)
is the second most frequent direct cause of
maternal death in Western Province, Kenya at
16% after haemorrhage (22%).2 In one district
hospital all women admitted during 2003 with
eclampsia died. There are also critical gaps3 in
health care provider knowledge, skills and
practice in management of eclampsia.
In Essential Obstetric Care and Life Saving
Skills training the use of MgSO4 is advocated
and many health care providers know about it
in theory but the drug is difficult to obtain and
is not part of the essential drugs list available
to public health facilities.
Emergency resuscitation trays in maternity
units do not always have essential components
required: patella hammer (for testing reflexes
in patient on MgSO4), calcium gluconate
(antidote to MgSO4) and uristix to detect
protein in the urine.
Although the use of MgSO4 was introduced
successfully to the Maternity Unit at Kenyatta
National Hospital, Nairobi in 2001, there has
been no systematic introduction of the drug
across the country.  Generally the only facilities
utilising MgSO4 are those supported by
development partners and some mission
hospitals.
In response to health care managers and
providers request in Western Province to be
trained in the use of MgSO4, a two-day
practical training programme was developed.
Training
The main objective for the On Job Training was
to ensure that participants had specific skills
of preventing and managing severe pre
eclampsia and eclampsia. In addition the
necessary equipment, supplies and MgSO4
were made available to the facilities where
health care providers were trained. Laminated
flow-charts illustrating the administration of the
drug were distributed for display in the
maternity units.
During support supervision two months after
the two day training the following were found:
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1 WHO 1994
2 Population Council, MOH, UoN 2004 SMDP Western
Province Approaches to providing quality maternal
care in Kenya report
3 Population Council, MOH, UoN Baseline Survey 2002
but specifically at the facility level and the drug
must be placed on the Essential Drug List.  The
following issues will need to be included in the
RH policy:
Magnesium Sulphate for the
management of PIH to be licensed
Magnesium sulphate to be manufactured
in Kenya – within hospitals or
institutions regulated to do so.
Advocacy at all levels to inform women,
families and communities on
effectiveness of drug
Ensure effective Focussed Antenatal Care
to detect signs of pre-eclampsia early
Ensure equipment and supplies are
available for prevention of HIP specifically
BP machines and uristix (for detection of
proteinuria) at all levels of health facility.
Conclusion
International and national
evidence has proved MgSO4 as
the drug of choice for the
management of pregnancy
induced hypertension/
eclampsia. Practical training can
take place on the ward within
one day with close supervsion.  MgSO4 is both
cheap and effective and has already saved
many lives since it was introduced in Western
Province.
“It is a wonder drug, the patient 
stopped convulsing and was 
fully conscious all through, had 
a normal vaginal delivery and 
after 4 days was discharged 
with her baby.” 
33 out of 44 (75%) of maternity staff
interviewed were comfortable using
MgSO4
9 out of 15 (60%) of eclamptic mothers
had received MgSO4
All 6 mothers admitted to PGH with
severe pre-eclampsia were treated
successfully with MgSO4
Twenty-nine mothers admitted with
severe pre-eclampsia in the other
hospitals did not receive MgSO4 as
providers were only using it for patients
who were convulsing. More MgSO4 was
made available and further OJT rectified
this.
There were no adverse effects reported
on mothers who received MgSO4
• Staff who had attended the training









programme such as this include:
Reluctance of some senior health care
providers to introduce the drug in their
facilities due to lack of up to date
information
Ensuring essential drugs, supplies and
equipment always available
Continuous education to ensure newly
deployed staff are conversant in use of
Mg SO4
Late referrals from the community;
Policy Implications
For Magnesium Sulphate to become the routine
drug of choice for the management of
pregnancy-induced hypertension, this
information must be disseminated and
clarified at all levels
